Accumulating evidence indicates that epigenetic alterations contribute to exacerbated activation or deregulation of the mechanisms that maintain tolerance to self-antigens in patients with lupus, a systemic autoimmune disease that can be triggered by medications taken to treat a variety of conditions. Here, we tested the effect of hydralazine, an antihypertensive drug that triggers lupus, on receptor editing, a chief mechanism of B lymphocyte tolerance to self-antigens. Using mice expressing transgenic human Igs, we found that hydralazine impairs up-regulation of RAG-2 gene expression and reduces secondary Ig gene rearrangements. Receptor editing was also partially abolished in a dose-dependent manner by a specific inhibitor of MEK1/2. Adoptive transfer of bone marrow B cells pretreated with hydralazine or with a MEK inhibitor to naïve syngeneic mice resulted in autoantibody production. We conclude that, by disrupting receptor editing, hydralazine subverts B lymphocyte tolerance to self and contributes to generation of pathogenic autoreactivity. We also postulate that inhibition of the Erk signaling pathway contributes to the pathogenesis of hydralazine-induced lupus and idiopathic human lupus.
D
rug-induced lupus (DIL) is a systemic autoimmune disease that can be induced by over 40 medications, including the antihypertensive drug hydralazine and the antiarrhythmic drug procainamide (1) . In the patient, the drug reaches a steady-state concentration within a few hours, but the symptoms require several months to develop and fade with therapy discontinuation. Intriguingly, there is no apparent common chemical structure or pharmacologic property among the various medications that trigger similar laboratory and clinical features, and the disease is clinically indistinguishable from idiopathic lupus. Likewise, the mechanisms underlying the induction of DIL remain unclear.
The ability of the immune system to distinguish self from non-self is central to its capacity to protect against pathogens and, at the same time, maintains tolerance to its own components. This seminal property is established at discrete nodes, both during early development and adulthood. In the B lymphocyte compartment, several mechanisms have been identified (2) . They include clonal deletion of autoreactive lymphocytes, clonal anergy, which converts autoreactive cells to a state that precludes them from becoming activated, and receptor editing, a mechanism that modifies self-reactive B cells and renders them nonautoreactive (3, 4) . This latter process can extinguish autoreactivity by displacing a productively rearranged Ig heavy (H)-or light (L)-chain gene by secondary gene rearrangements, forming edited antigen (Ag) receptors with no, or reduced autoreactivity. Importantly, it also represents a powerful mechanism by which autoreactive cells can be generated or fail to be eliminated (5, 6) . Editing depends on the products of recombinase activator genes (RAG-1 and RAG-2), and uses the same recombination machinery that mediates primary VDJ rearrangement events. It occurs mainly on the Ig locus through V to J secondary rearrangements (3, 4) . However, the secondary VJ rearrangements may be nonproductive, or productive, but encoding Ig chains that do not preclude autoreactivity. In these cases, recombination of Ig genes and expression of Ig L-chains follows the inactivation of the Ig locus, an event also mediated by RAG-1 and RAG-2 (7). In addition, editing also occurs at the IgH locus although V H to V H DJ H replacements (8) .
Studies of Ig-transgenic animal models revealed that clonal deletion and receptor editing occur at distinct developmental stages during B cell development in the bone marrow (BM), and that editing is an efficient mechanism that can potentially rescue autoreactive B cells from clonal deletion (7, 9, 10) . On contact with self-Ag, immature B cells are preferentially induced to undergo secondary Ig gene rearrangements to alter their selfreactive specificity. Cells that fail to edit their autoreactive Ag receptors are prone to apoptotic deletion even before entering the mature B cell pool. Compared with mature B cells, immature B cells are highly sensitive to clonal deletion or receptor editing, even when they encounter low-affinity (1 ϫ 10 4 to 1 ϫ 10 6 liters/mole) membrane-bound autoAgs in a polyclonal and diverse B cell population (11) . In that setting, editing can occur with an efficiency approaching 100% and with minimal cell loss.
Because receptor editing represents a chief mechanism of B cell tolerance to self-Ags that can function in the apparent absence of cell loss, defects in receptor editing may contribute to generation of pathogenic autoreactivity. Using transgenic mice expressing human Igs and hydralazine at therapeutically relevant concentrations, we asked whether this lupus trigger can disrupt receptor editing and subvert B cell tolerance to self. encompassing the C coding region, the complete J cluster, the first three J -proximal V 4-1, V 5-2, and V 7-3 gene segments, as well as V genes belonging to the V 1, V 2, and V 3 families [see supporting information (SI) Fig. 6 ]. The transgenic rodents, called five-feature mice, produce B lymphocytes that secrete fully human Abs (19) .
Antigen Receptor Cross-Linking Promotes RAG Gene Expression in
Immature B Cells. The use of BM immature B lymphocytes allows detection of receptor editing because in these cells RAG expression and Ig rearrangements are suppressed in the absence of self-Ag (3). Therefore, we used RT-PCR to probe RAG gene expression in BM cell cultures. Accordingly, control and antiIgM-treated cells were analyzed for markers of receptor editing. As expected, untreated BM cells had low levels of RAG-2 mRNA that were unaffected by treatment with vehicle, whereas treatment with anti-human IgM F(abЈ) 2 fragments stimulated RAG-2 expression ( Fig. 1 A and B) . BcR cross-linking consistently led to a significant (P Ͻ 0.005) increase in RAG-2 mRNA levels over several experiments. The appearance of bands corresponding to RAG-2 transcripts was strictly dependent on prior reverse transcription, indicating that the amplified cDNA fragments did not derive from contaminated genomic DNA. We conclude that BcR ligation of BM B cells results in up-regulation of RAG-2 gene expression, a property that ensures that autoreactive, immature B cells do not mature into potentially harmful autoreactive, mature B cells.
BcR Ligation Induces L-Chain Gene Rearrangements in Ig ؉ Bone
Marrow B Cells. One indicator of receptor editing commonly considered for analysis of the human V locus is the proximity of V genes used. A distal V -J gene secondary rearrangement can delete a more proximal V -J primary gene rearrangement. As a result, evidence of receptor editing is a V -J repertoire skewed to the more distal V gene segments. However, the existence of a number of inverted V genes in the human locus that rearrange by inversion rather than deletion of the intervening sequence (18) complicates analysis of the V repertoire for editing. Because V 4-1 is the most J -proximal gene, any primary rearrangement of an upstream inverted V gene will result in its inversion and availability for secondary rearrangements. This prediction was verified by showing that the increased frequency of V 4-1-J rearrangements in B cells results from extensive receptor editing (20) . Additionally, the V 4-1 segment was found to be over-represented in isolated human B cells that were in the process of receptor editing (17) . Thus, because of the position of V 4-1 and its orientation in the V locus, analysis of V 4-1-J rearrangements provides a measure of receptor editing for all V genes.
By RT-PCR, we found that unstimulated BM cells from five-feature mice express various levels of V -J 5 gene family rearrangements: V 4-J 5: 35%; V 1-J 5: 30%; V 3-J 5: 22%; and V 5-J 5: 12%. These expression patterns are in agreement with estimates based on sequence analysis of hybridomas (19) , and on single-cell PCR analysis and nucleotide sequencing of B cells from five-feature mice (21) . Treatment of BM cells with anti-human IgM F(abЈ) 2 fragments shifted the V -J 5 rearrangement patterns, with a marked increase of V 4-J 5 (from 35% to 50%) and, to a lower extent, V 1-J 5 (from 30% to 43%) rearrangements ( Fig. 1 C and D) . These data show that BcR ligation can induce extensive L-chain gene rearrangements in Ig ϩ BM B cells from transgenic mice harboring a human -chain translocus.
BcR Ligation Specifically Induces -Chain Expression on Immature B
Cells. L-chain rearrangement is an ordered process (V, then V), and increased V usage has been associated with receptor editing (9) . In the BM of five-feature mice, untreated B cells expressed -L chains on Ϸ8% of B220 ϩ lymphocytes. Treatment with anti-human IgM F(abЈ) 2 fragments (10 g/ml) induced an increase in the percentage of cells expressing -L chains ( Fig. 2  A and B) . Consistently, cultures treated with 10 g/ml of anti-human F(abЈ) 2 fragments expressed -L chains on Ϸ22% of the lymphocytes, a statistically significant increase. This increase was also reflected in the absolute numbers of ϩ cells recovered from the cultures. These results indicate that in BM cultures from human Ig transgenic mice, BcR ligation specifically induced L-chain expression on, at least, a subset of immature B cells. BcR Ligation Does Not Accelerate Death of Bone Marrow B Cells. To see whether BcR engagement induced cell death, BM cells from five-feature mice were cultured in the absence or presence of 10 g/ml of anti-human IgM or anti-F(abЈ) 2 fragments, and B cell survival was assessed by annexin V/propidium iodine labeling. At this Ab concentration, both anti-IgM and anti-rapidly downmodulated BcR expression. After 3 d of culture, anti-IgM and anti-treatments did not appreciably reduce B cell recovery from BM cells (Fig. 2C) . Thus, under these conditions, BcR ligation did not markedly accelerate B cell death.
Hydralazine Impairs Receptor Editing in IgM ؉ Bone Marrow B Cells.
We next probed the potential effects of hydralazine, an antihypertensive drug that triggers lupus in patients, on receptor editing. BM cells from mice transgenic for human Ig loci were pretreated with the drug or with vehicle at the indicated doses at 37°C for two hours. When cells were cultured with anti-human IgM F(abЈ) 2 fragments (1 and 10 M), hydralazine decreased up-regulation of RAG-2 gene expression, diminished successive V gene rearrangements as measured by the amount of V 4-J 5 rearrangements (Fig. 3) , and antagonized -chain 3 -chain shifting (Fig. 4) . Thus, the lupus trigger hydralazine is able to subvert the process of receptor editing under conditions mimicking the encounter of self-reactive B cells with autoAg in the BM and leading to BcR-induced negative selection.
Blocking Erk Activation Subverts Receptor Editing. Studies have shown that sustained Erk activation can lead to the initiation of transcription of genes involved in both proliferation and cellular survival. In anergic T cells, however, T cells exhibit a defective activation of the Ras-MEK-Erk1/2 pathway (22) . In B cells too, signaling differences in response to BcR engagement have been documented between immature and mature B cells (23) , and between naïve B cells that have not encountered Ags and tolerant B cells that were chronically exposed to self-Ags (24) .
We therefore asked whether the BcR-mediated signals converge at the level of MEK-Erk kinases to guide the fate of B cells toward receptor editing. To see whether the Erk signaling pathway is involved in receptor editing elicited by BcR ligation, we used PD98059, a potent and selective MEK cell-permeable inhibitor of MAP kinase kinase (also known as MAPK/Erk kinase or MEK). PD98059 does not inhibit MAP kinase itself, but it blocks phosphorylation of MAP kinase by MAP kinase kinase (25) . First, we examined the influence of the MEK inhibitor PD98059 on V gene rearrangements. BM cells from five-feature mice were incubated with the pharmacological inhibitor PD98059 or vehicle for 2 h before stimulation with anti-human IgM F(abЈ) 2 fragments. Inhi- bition of MEK had clear effects on rearrangements, as shown by the results presented in Fig. 3 . The addition of 10 M of PD98059 to BM cell cultures also partially abrogated -chain 3 -chain shifting (Fig. 4) . We conclude that receptor editing is partially abolished in a dose-dependent manner by treatment with a specific inhibitor of MEK1/2 that blocks Erk1/2.
Impaired Receptor Editing Leads to AutoAb Production in Vivo.
We then designed experiments to determine whether subversion of receptor editing by a pharmacological inhibitor of Erk also leads to a breach in B cell negative selection in vivo and triggers autoAb production. To accomplish this, BM cells from fivefeature mice were preincubated in vitro with either PD98059 or vehicle, and then transferred to syngeneic mice. Sera were collected from all mice and assayed for Abs to a subnucleosomal preparation (H2A/H2B/DNA) by ELISA. As shown in Fig. 5 , BM cells that had been cultured with PD98059 mediated anti-nuclear Ab production in five-feature host mice, whereas control cells failed to produce autoAbs. We then tested the possible modulating effects of hydralazine. Here, too, transfer of BM cells that had been precultured in vitro with hydralazine to syngeneic mice gave rise to elevated titers of anti-subnucleosome Abs (Fig. 5) .
Discussion
Even though the origin of systemic autoimmune diseases remains under investigation, it is generally accepted that genetic and environmental factors are required for disease expression. In lupus, studies of affected identical monozygotic twins, in whom the highest estimated concordance rate is Ͻ60% suggest that environmental factors influence the onset and/or the disease course (26) . The high incidence of twin pairs in which only one of the siblings has developed lupus also supports the notion that epigenetic alterations are involved in disease progression. In this report, we show that hydralazine, a drug known to trigger human lupus, is able to impair receptor editing, a chief mechanism that contributes to maintain B cell tolerance to self, and to induce autoAbs in mice. We propose that through its propensity to subvert receptor editing, hydralazine represents an epigenetic factor that plays a role in triggering the disease onset in genetically predisposed individuals.
During B cell development of healthy donors, 55-75% of early B cell precursors express self-reactive Abs, and autoAb producing B cells are removed from the repertoire at two discrete nodes (27) . The first checkpoint occurs in the BM between the early immature and immature B cell stages. The second counterselection step of autoAb-expressing B cells takes place in the periphery, at the transition from new emigrant to mature naive B cells. In lupus, most patients fail to efficiently remove polyreactive B cells and reveal defects at early B cell tolerance checkpoints (28, 29) . Their L-chain autoAb sequences show an increase in downstream V genes associated with the most upstream J , suggesting inefficient secondary recombination and therefore a potential defect in receptor editing (14, 15) . In RA patients, central and peripheral B cell tolerance checkpoints are also defective, and this loss of tolerance is, at least in part, due to receptor editing impairments (30) . Consistently, biased V gene repertoires were observed in new emigrant B cells from three patients and may reflect abnormal BM B cell development (30) . Lack of receptor revision was also suggested to contribute to the autoimmune pathogenesis of oligoarticular juvenile idiopathic arthritis (31) . Together, the available evidence suggests that 5 . Treatment of bone marrow cells from transgenic mice with hydralazine or a MEK inhibitor induces autoantibody production in syngeneic animals. Bone marrow cells from five-feature transgenic mice that had been cultured with PD98059, hydralazine, or vehicle (DMSO) were injected five times into syngeneic rodents. Fourteen days after the final cell transfer, autoAb production was tested in mouse sera diluted 1/100 to 1/400 by ELISA. Raw optical densities were converted to units/ml (U/ml) with a positive control serum for anti-histone/DNA ELISA, arbitrarily setting the reactivity of a 1:100 dilution of the positive control serum to 50 units/ml. Groups receiving either PD98059-, or hydralazine-treated BM cells had statistically significant increased titers compared with the group receiving vehicle-treated BM cells (P Ͻ 0.001).
abnormal receptor editing represents a pathogenic feature shared by different rheumatic diseases. The experiments described herein identify, for the first time, a drug capable of triggering DIL as a causing factor of receptor editing impairment.
Antigen binding to the BcR can lead to activation, proliferation and differentiation, or tolerance. These distinct cell outcomes depend, in part, on the developmental stage of the lymphocyte and on the coordinate regulation of signaling pathways. The resulting signals quickly reach the nucleus and alter gene expression, leading to various cellular responses. In immature B cells, they typically cause them to enter into an anergic state, to undergo apoptosis or to edit their receptors, responses that maintain immunological self-tolerance (2). Because BcR signaling plays an important role in controlling receptor editing by regulating RAG genes (5, 12, 13, 32, 33) , defects in BcR signaling can result in failure to induce receptor editing, premature termination of secondary rearrangements at the immature B cell stage, or even accelerated editing. For example, in the absence of the Bruton tyrosine kinase (Btk), peripheral B cells show a distinct Ab repertoire consistent with extensive secondary L-chain rearrangements (33) . It also is striking that immature B cells expressing signaling-incompetent receptors are positively selected rather than die, and may generate autoimmunity in mice. Thus, mice lacking SHP-1, CD45, CD22, or Lyn produce autoAbs and suffer from immune complex-mediated nephritis (34) . Consistently, human lupus B cells that suffer from defective tolerance exhibit abnormal BcR signaling (34, 35) . Several observations also indicate that the ras-MAPK pathway is defective in lupus patients (36) (37) (38) and aberrantly activated in B cells from lupus mice bearing the Sle1 gene cluster (39) . Our demonstration that blocking this pathway alters receptor editing in vitro and promotes autoreactivity in vivo is also consonant with the phenotype of mice lacking SPA, a regulator of MAP kinases, including Erk and p38 MAPK (40) . SPA-1 Ϫ/Ϫ mice exhibited an expansion of autoreactive B cells, produced anti-dsDNA Abs, and developed a lupus-like syndrome (41) . Their immature B cells showed ineffective receptor editing of V genes with a significantly altered repertoire, suggesting that this bias may have favored the generation of autoreactive immature B cells. Thus, absence of the SPA-1 signaling molecule (41) or partial blocking of the Raf-MEK-Erk signaling pathway (this report) alter V gene repertoire expression, impair receptor editing in immature B cells and give rise to self-reactive B cells in vivo.
As a first step in characterizing the in vivo effects of hydralazine on B cell tolerance, we have performed syngeneic BM transfer experiments of cells exposed to the drug. The mice developed high titers of autoAbs, indicating that the subversion of receptor editing observed in vitro translates to a break in self-tolerance in vivo. The results strongly imply that hydralazine directly impacts B cells and contributes to loss of humoral tolerance to nuclear Ags, an important component of DIL. Remarkably, hydralazine also decreases Erk phosphorylation in T cells in response to in vitro stimulation, and T cells treated with an Erk pathway inhibitor trigger anti-dsDNA Abs in vivo (42) . Because the lymphocyte Erk signaling pathway is impaired in patients with active lupus (37, 38) , in hydralazine-treated T cells (42) , and in experimental lupus (39) , it is possible that this T cell signaling defect contributes to disease pathogenesis. Our current observations suggest that the Erk signaling pathway is also impaired in B cells, providing a novel potential unifying T and B cell-mediated mechanism for the development of autoimmunity in both idiopathic and hydralazine-induced lupus.
Because of the relationship of hydralazine to the induction of human lupus and the need to establish an experimental model, several investigators have tested the effects of the drug in animals, including mice, guinea pigs, rats, rabbits and pigs. In rodents, oral administration of hydralazine was able to trigger the appearance of antinuclear autoantibodies in females and males of the BALB/c, C57BL/6 and A/Jax mouse strains (43, 44) . Reminiscent of clinical observations in patients, when the drug was withdrawn, some previously positive mice became negative for antinuclear Ab (ANA). However, the mechanisms responsible for the emergence of autoreactivity remained unclear. Here, we have demonstrated that hydralazine, used at therapeutically relevant concentrations (ϳ10 M), disrupts induction of receptor editing. We would like to offer the following model to account for this tolerance subversion. Hydralazine is known to interact with chromatin or its components, and to inhibit DNA methylation (45) . Because DNA methylation plays a role in the regulation of gene expression, and because methylation/ demethylation controls V gene rearrangements during lymphocyte differentiation (46) , changes in DNA methylation provide a molecular basis for a deficit in editing of self-reactive B cells in lupus (47) . The view that abnormal DNA methylation of the V locus alters the B cell's propensity to undergo successive rearrangements may explain how chemically dissimilar drugs can subvert self-tolerance and induce the same disease, DIL. However, we must emphasize that in addition to impacting RAG gene expression and receptor editing, hydralazine may have a pleiotropic effect that includes other features like interfering with cell cycle division and activation status. For example, mice lacking protein kinase C␦, an enzyme implicated in the inhibition of cell growth, differentiation and apoptosis, exhibit increased proliferation of B cells and autoimmunity (reviewed in ref. 35 ). It will therefore be useful to test the potential effects of the drug on cell cycle regulators.
In addition to medications, environmental agents have been associated with lupus. For example, aromatic amines and hydralazines, and their derivatives, can be found in a wide variety of compounds used in agriculture and industry, and lupus-like syndromes have been reported in individuals who have been in contact with these agents. Hydralazine itself occurs in tobacco and tobacco smoke, and cigarette smokers have a significantly higher risk of dsDNA seropositivity and of developing lupus (48) . It is possible that such xenobiotics act by subverting the Ras-MEK-Erk1/2 signaling pathway, giving rise to clones unable to properly sense the presence of ligands. In the B cell compartment, such clones would be functionally equivalent to immature B cells that undergo little Ig L-chain gene recombination, counterselecting elimination of self-reactive B cells and releasing them into the periphery.
Materials and Methods
Generation of the five-feature transgenic mice used has previously been described (19) . Briefly, the endogenous loci coding for the H-and L-chains have been inactivated, and human H-, -and -chain transloci were ''knocked-in.'' The H-chain translocus contains the core region of the human H-chain locus with the five most 3Ј V H gene segments, the complete D H and J H loci, and the C and C␦ exons in correct germ-line configurations. The -chain translocus is a construction that includes 20 repeats of five V gene segments linked to the core of the germ-line locus, including the first three V gene segments, the complete J cluster and the C coding region. It contains 82 functional V gene segments. Finally, the -chain translocus encompasses 28 V gene segments (with 16 functional) attached to the J and C coding regions in the correct germ-line configuration. Mice were bred and maintained in the animal care facility of Broussais Hospital (Paris) and used at 7-9 weeks of age in accordance with protocols approved by ad hoc care committees. They were housed in a specific pathogen-free barrier facility.
Isolation and stimulation of B lymphocytes, fluorescence staining and phenotypic analysis, measurement of RAG-2 expression and of V-J rearrangements for receptor editing, bone marrow (BM) transfer experiments, quantitation of serum autoAbs, and statistical analysis are described in SI Methods.
